Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Objective Immunogenicity and safety following receipt of the standard SARS–CoV‐2
vaccination regimen in patients with immune‐mediated inflammatory diseases (IMIDs) are …

Background Two years into the pandemic, convincing evidence in favour of convalescent
plasma (ConvP) as a treatment for coronavirus disease 2019 (COVID-19) is still lacking. This …

Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure
levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt) …

Data on convalescent plasma (CP) treatment in COVID-19 outpatients are scarce. We aimed
to assess whether CP administered during the first week of symptoms reduced the disease …

Background The aim of this randomized, controlled trial is to determine whether antisevere
acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against …

Functional immunity (defined here as serum neutralising capacity) critically contributes to
conferring protection against SARS-CoV-2 infection and severe COVID-19. This cross …

New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine
platform for preparedness against emerging viral pathogens. Applying platform optimization …

Virus neutralization assays provide a means to quantitate functional antibody responses that
block virus infection. These assays are instrumental in defining vaccine and therapeutic …

The emergence of SARS-CoV-2 variants stresses the continued need for broad-spectrum
therapeutic antibodies. Several therapeutic monoclonal antibodies or cocktails have been …